



BioMab, Inc. discovers and develops cutting edge immune-based diagnostics and therapeutics to enable healthcare professionals to provide patients with personalized care.

The company was founded through close collaboration with a leading research group specializing in the field of antibody technologies and targeted therapy at Academia Sinica, Taiwan.



- Highest binding affinity EpCAM antibody on the market ($K_d < 10^{-12}$)
- CTC capture rate > 95%
- Capturing live CTCs for culturing (success rate > 96%)

Positive CTC Selection Platform


- GMP production
 - 2 paper citations by CellSearch Inventor (Professor Leon Terstappen)
 - Ongoing clinical studies in breast, colorectal, gastric and head, Non-small cell lung cancer & neck cancers with major hospitals in Taiwan
- Automation instrument available




Liquid Biopsy

Most sensitive CTC reagent


BioMab



Non-small cell lung cancer Patient #3 – After Treatment



Capturing Efficiency in Buffer



Competitive Advantages

- Simple testing procedure (no need for microfluidic chips)
- High sensitivity – 2-4X more sensitive than other platforms
- Can capture CTCs that other platforms cannot (low EpCAM expressing cells, such as MBA-MD-231)
- Capture live CTCs for subsequent whole genome sequencing (success rate > 96%)
- CTCs are successfully identified in > 95% of the patients

For more information, please contact us at

contact@biomabinc.com

<http://www.biomabinc.com>

